ESMO 2019 | Predicting resistance to targeted therapies in melanoma

Christian Blank

Christian Blank, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, outlines how we might be able to predict resistance to targeted therapies in melanoma patients. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video